Catalent joins the EuropaBio 25th Anniversary in 2021
EuropaBio today announced that Catalent has joined EuropaBio’s 25th Anniversary Celebration Programme as a major sponsor.
EuropaBio today announced that Catalent has joined EuropaBio’s 25th Anniversary Celebration Programme as a major sponsor.
Catalent today announced it has appointed Mike Grippo as Senior Vice President, Strategy and Corporate Development. Alongside his appointment, Julien Meissonnier has been named as Vice President and Chief Scientific Officer, and will report to Mr. Grippo.
Catalent today announced a collaboration with Johnson & Johnson for large-scale commercial manufacturing at its facility in Bloomington, Indiana of Johnson & Johnson’s lead vaccine candidate for COVID-19.
Catalent today announced the completion of its $14 million expansion to increase the biologics packaging capabilities and capacity at its Bloomington, Indiana facility.
Catalent has completed the expansion of two new suites at its biologics drug substance development and manufacturing facility in Madison, Wisconsin, and has now commenced work on customer programs.